U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H16NO7P2.Na
Molecular Weight 299.131
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NERIDRONATE SODIUM

SMILES

[Na+].NCCCCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

InChIKey=MHYULJPRWPTMTD-UHFFFAOYSA-M
InChI=1S/C6H17NO7P2.Na/c7-5-3-1-2-4-6(8,15(9,10)11)16(12,13)14;/h8H,1-5,7H2,(H2,9,10,11)(H2,12,13,14);/q;+1/p-1

HIDE SMILES / InChI

Description
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02972359 | https://clinicaltrials.gov/ct2/show/NCT02402530 | https://www.drugs.com/international/nerixia.html | https://www.ncbi.nlm.nih.gov/pubmed/19748562 | https://www.ncbi.nlm.nih.gov/pubmed/17574655

Neridronic acid (6-amino-1-idroxyesilidene-1,1-bisphosphonate) is a nitrogen-containing bisphosphonate licensed in Italy for the treatment of osteogenesis imperfecta and Paget’s disease of bone. The pharmacodynamic profile is similar to that of other nitrogen-containing bisphosphonates and is characterized by its high affinity for bone tissue particularly at sites undergoing a process of remodeling. In growing children affected by osteogenesis imperfect, neridronic acid rapidly increases bone mineral density as measured by dual X-ray absorptiometry and this is associated with a significant decrease in fracture cumulative number. Similar results have been obtained also in newborns (<12-month-old) and in adult patients. In Paget’s disease of bone, 200 mg intravenous neridronic acid is associated with a 65% rate of full remission and a biochemical response (decrease of > 75% of bone turnover markers) in 95% of the patients. Neridronic acid treatment has been reported to be effective also in other skeletal diseases such as osteoporosis, algodystrophy, hypercalcemia of malignancy and bone metastasis. Neridronic acid has been developed only for parenteral use, and it is the only one used as the intramuscular injection. This avoids all the limitations of oral bisphosphonates and may be offered for a home treatment with simple nursing assistants

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Nerixia

Approved Use

Unknown
Primary
Nerixia

Approved Use

Unknown
Primary
Nerixia

Approved Use

Unknown
Primary
Nerixia

Approved Use

Unknown
Primary
Nerixia

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta.
2005 Aug
Study of pepsin phosphorylation using immobilized metal affinity chromatography.
2008 Jun
Intramuscular neridronate in postmenopausal women with low bone mineral density.
2008 Nov
Patents

Sample Use Guides

Neridronic acid is licensed in Italy for the treatment of Paget’s disease at the dose of 100 mg dissolved in 250 ml of saline solution given i.v. for 2 consecutive days. Neridronic acid 25 mg i.m. monthly is also effective in fully preventing the changes in bone turnover markers and BMD associated with androgen deprivation therapy for prostatic cancer
Route of Administration: Other
MDA-MB-231, U87-MG and Caco2 cells were used for activity evaluation. Cells were seeded at a density of 10^4 cells per well in 96-well flat-bottom plates (Falcon, Strasbourg, France) and incubated in completed culture medium for 24 h. Then, medium was removed and replaced by 10% FCS-medium containing increasing concentrations of neridronate from 16 nkM to 1 mM and varying concentration of liposomal suspension containing neridronate from 0.27 mkM to 17.56 mkM. After 72 h incubation (free neridronate) or 24 h, 48 h and 72 h incubation (liposomal neridronate), cells were washed with phosphate buffered saline (PBS, Life Technologies) and incubated with 0.1 ml of MTT (2 mg/ml, Sigma–Aldrich) for additional 4 h at 37 C. The insoluble product was then dissolved by addition of 100 mkl of DMSO (Sigma–Aldrich). The absorbance corresponding to the solubilized formazan pellet (which reflects the relative viable cell number) was measured at 570 nm using a Labsystems Multiskan MS microplate reader. Dose–response curves were obtained for free and liposomal neridronate concentrations, allowing the determination of EC50 values, which refer to the concentration inducing a response halfway between the baseline and the maximum plateau reached.
Name Type Language
NERIDRONATE SODIUM
MART.   WHO-DD  
Common Name English
NERIDRONATE SODIUM [MART.]
Common Name English
NERIDRONATE MONOSODIUM
Common Name English
NERIXIA
Brand Name English
NERIDRONIC ACID MONOSODIUM SALT [MI]
Common Name English
Neridronate sodium [WHO-DD]
Common Name English
NERIDRONIC ACID MONOSODIUM SALT
MI  
Common Name English
(6-AMINO-1-HYDROXYHEXYLIDENE)BISPHOSPHONIC ACID, SODIUM SALT
Common Name English
Code System Code Type Description
PUBCHEM
23669954
Created by admin on Fri Dec 15 18:41:47 GMT 2023 , Edited by admin on Fri Dec 15 18:41:47 GMT 2023
PRIMARY
DRUG BANK
DBSALT001937
Created by admin on Fri Dec 15 18:41:47 GMT 2023 , Edited by admin on Fri Dec 15 18:41:47 GMT 2023
PRIMARY
EVMPD
SUB27150
Created by admin on Fri Dec 15 18:41:47 GMT 2023 , Edited by admin on Fri Dec 15 18:41:47 GMT 2023
PRIMARY
CAS
80729-79-9
Created by admin on Fri Dec 15 18:41:47 GMT 2023 , Edited by admin on Fri Dec 15 18:41:47 GMT 2023
PRIMARY
SMS_ID
100000090336
Created by admin on Fri Dec 15 18:41:47 GMT 2023 , Edited by admin on Fri Dec 15 18:41:47 GMT 2023
PRIMARY
FDA UNII
H6JVB49Q0F
Created by admin on Fri Dec 15 18:41:47 GMT 2023 , Edited by admin on Fri Dec 15 18:41:47 GMT 2023
PRIMARY
MERCK INDEX
m7828
Created by admin on Fri Dec 15 18:41:47 GMT 2023 , Edited by admin on Fri Dec 15 18:41:47 GMT 2023
PRIMARY Merck Index